NO20073959L - Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller - Google Patents
Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftcellerInfo
- Publication number
- NO20073959L NO20073959L NO20073959A NO20073959A NO20073959L NO 20073959 L NO20073959 L NO 20073959L NO 20073959 A NO20073959 A NO 20073959A NO 20073959 A NO20073959 A NO 20073959A NO 20073959 L NO20073959 L NO 20073959L
- Authority
- NO
- Norway
- Prior art keywords
- preparation
- quinazoline derivative
- cancer cell
- cell growth
- inhibiting cancer
- Prior art date
Links
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000010261 cell growth Effects 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000005907 cancer growth Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20040114839 | 2004-12-29 | ||
| KR1020050111724A KR100735639B1 (ko) | 2004-12-29 | 2005-11-22 | 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법 |
| PCT/KR2005/004395 WO2006071017A1 (en) | 2004-12-29 | 2005-12-20 | Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20073959L true NO20073959L (no) | 2007-09-27 |
Family
ID=36615106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20073959A NO20073959L (no) | 2004-12-29 | 2007-07-27 | Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8003658B2 (es) |
| EP (1) | EP1844022B1 (es) |
| JP (1) | JP4914372B2 (es) |
| KR (2) | KR100735639B1 (es) |
| CN (1) | CN101094840B (es) |
| AU (1) | AU2005320472B2 (es) |
| BR (1) | BRPI0519474A2 (es) |
| CA (1) | CA2592286C (es) |
| ES (1) | ES2427445T3 (es) |
| IL (1) | IL183583A (es) |
| MX (1) | MX2007007458A (es) |
| NO (1) | NO20073959L (es) |
| NZ (1) | NZ556773A (es) |
| RU (1) | RU2362773C2 (es) |
| WO (1) | WO2006071017A1 (es) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7501427B2 (en) | 2003-08-14 | 2009-03-10 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| DK1660090T3 (da) | 2003-08-14 | 2012-12-17 | Array Biopharma Inc | Quinazolin-analoger som receptor-tyrosinkinase-inhibitorer |
| JP2008542356A (ja) * | 2005-06-03 | 2008-11-27 | ファイザー・プロダクツ・インク | 異常な細胞増殖の治療用の二環式誘導体 |
| ATE446294T1 (de) | 2005-11-15 | 2009-11-15 | Array Biopharma Inc | N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i- rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten |
| CN101003514A (zh) * | 2006-01-20 | 2007-07-25 | 上海艾力斯医药科技有限公司 | 喹唑啉衍生物、其制备方法及用途 |
| KR100929146B1 (ko) * | 2006-06-28 | 2009-12-01 | 한미약품 주식회사 | 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 |
| US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| AU2007296746B2 (en) * | 2006-09-11 | 2012-07-05 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| WO2008033747A2 (en) * | 2006-09-11 | 2008-03-20 | Curis, Inc. | Multi-functional small molecules as anti-proliferative agents |
| CN101245050A (zh) * | 2007-02-14 | 2008-08-20 | 上海艾力斯医药科技有限公司 | 4-苯胺喹唑啉衍生物的盐 |
| US8163923B2 (en) | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
| US8148532B2 (en) * | 2007-03-14 | 2012-04-03 | Guoqing Paul Chen | Spiro substituted compounds as angiogenesis inhibitors |
| US20120101114A1 (en) | 2007-03-28 | 2012-04-26 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| US20120065201A1 (en) * | 2007-03-28 | 2012-03-15 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| WO2008128231A1 (en) | 2007-04-16 | 2008-10-23 | Hutchison Medipharma Enterprises Limited | Pyrimidine derivatives |
| KR101397523B1 (ko) * | 2007-04-27 | 2014-05-30 | 한미약품 주식회사 | 다중저해제로서의 퀴나졸린 유도체 |
| CN101544609A (zh) | 2008-03-25 | 2009-09-30 | 上海艾力斯医药科技有限公司 | 4-苯胺喹唑啉衍生物的结晶形式 |
| US7829574B2 (en) | 2008-05-09 | 2010-11-09 | Hutchison Medipharma Enterprises Limited | Substituted quinazoline compounds and their use in treating angiogenesis-related diseases |
| CN101584696A (zh) | 2008-05-21 | 2009-11-25 | 上海艾力斯医药科技有限公司 | 包含喹唑啉衍生物的组合物及制备方法、用途 |
| US8426430B2 (en) | 2008-06-30 | 2013-04-23 | Hutchison Medipharma Enterprises Limited | Quinazoline derivatives |
| US7737157B2 (en) | 2008-08-29 | 2010-06-15 | Hutchison Medipharma Enterprises Limited | Pyrimidine compounds |
| ITMI20082336A1 (it) * | 2008-12-29 | 2010-06-30 | Univ Parma | Composti inibitori irreversibili di egfr con attivita' antiproliferativa |
| US8575203B2 (en) | 2010-04-21 | 2013-11-05 | Boehringer Ingelheim International Gmbh | Chemical compounds |
| CA3007787C (en) | 2010-06-03 | 2020-03-10 | Pharmacyclics Llc | The use of inhibitors of bruton's tyrosine kinase (btk) |
| CN102311438A (zh) * | 2010-06-30 | 2012-01-11 | 和记黄埔医药（上海）有限公司 | 喹唑啉化合物 |
| CN102906086B (zh) * | 2010-06-30 | 2014-02-12 | 和记黄埔医药（上海）有限公司 | 喹唑啉化合物 |
| CN102485735B (zh) * | 2010-12-02 | 2014-09-24 | 东莞南方医大代谢医学研发有限公司 | 6-果糖氨-4-芳胺基喹唑啉衍生物及其用途 |
| JP2014520863A (ja) | 2011-07-13 | 2014-08-25 | ファーマサイクリックス，インク． | Ｂｒｕｔｏｎ型チロシンキナーゼの阻害剤 |
| JP6437820B2 (ja) | 2011-07-27 | 2018-12-12 | シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド | キナゾリン誘導体、その製造方法、中間体、組成物及びその適用 |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| EP2752413B1 (en) * | 2012-03-26 | 2016-03-23 | Fujian Institute Of Research On The Structure Of Matter, Chinese Academy Of Sciences | Quinazoline derivative and application thereof |
| CN103360382B (zh) * | 2012-03-26 | 2016-04-27 | 中国科学院福建物质结构研究所 | 喹唑啉衍生物及其用途 |
| CN104704129A (zh) | 2012-07-24 | 2015-06-10 | 药品循环公司 | 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变 |
| CN103102315B (zh) * | 2012-11-01 | 2016-01-20 | 云南大学 | 一种喹唑啉类芳基脲及其制备方法和用途 |
| CN102942561A (zh) * | 2012-11-06 | 2013-02-27 | 深圳海王药业有限公司 | 4-氨基喹唑啉杂环化合物及其用途 |
| CN103275018B (zh) * | 2013-04-26 | 2016-03-02 | 浙江工业大学 | 4-[3-氯-4-取代苯胺基]-6-取代甲酰氨基喹唑啉类化合物及制备和应用 |
| CN103288758B (zh) * | 2013-05-16 | 2015-01-21 | 苏州明锐医药科技有限公司 | 一种达克米替尼的制备方法 |
| BR112016006978A2 (pt) | 2013-09-30 | 2017-08-01 | Pharmacyclics Llc | inibidores de tirosina quinase de bruton |
| CN103570692A (zh) * | 2013-10-31 | 2014-02-12 | 浙江大学 | 含吖丙啶环侧链的喹唑啉衍生物及制备和应用 |
| US9643917B2 (en) * | 2014-02-17 | 2017-05-09 | Jiangsu Nhwaluokang Pharmceutical Research And Development Co., Ltd | Water-soluble propofol derivatives and uses thereof |
| US10239851B2 (en) | 2014-02-17 | 2019-03-26 | Qingeng Li | Carboxylic acid derivatives and use thereof in the preparation of prodrugs |
| US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
| NZ732511A (en) | 2014-12-15 | 2018-11-30 | Univ Michigan Regents | Small molecule inhibitors of egfr and pi3k |
| CN106117182B (zh) * | 2016-06-20 | 2019-08-30 | 中国药科大学 | 喹唑啉-n-苯乙基四氢异喹啉类化合物及其制备方法和应用 |
| JP2020023441A (ja) * | 2016-11-02 | 2020-02-13 | 国立大学法人九州大学 | Ｅｇｆｒ阻害及び腫瘍治療に有用な新規化合物 |
| BR112021004527A2 (pt) * | 2018-09-14 | 2021-06-08 | Spectrum Pharmaceuticals, Inc. | kits e métodos para tratamento contra câncer |
| US20240239764A1 (en) | 2020-12-22 | 2024-07-18 | Mekanistic Therapeutics | Substituted aminobenzyl heteroaryl compounds as egfr and/or pi3k inhibitors |
| CN115948325B (zh) * | 2022-12-15 | 2025-08-29 | 睿健毅联医药科技(成都)有限公司 | 一种诱导间质细胞向上皮细胞转化及重编程的诱导剂 |
| CN118652239A (zh) * | 2024-05-29 | 2024-09-17 | 江南大学 | 一类egfr别构抑制剂的合成及其用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
| GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| TW436485B (en) * | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| SI20582A (sl) * | 2000-05-05 | 2001-12-31 | Univerza V Ljubljani | Novi inhibitorji trombina, njihova priprava in uporaba |
| EP1292591B1 (en) | 2000-06-22 | 2005-02-02 | Pfizer Products Inc. | Substituted bicyclic derivatives for the treatment of abnormal cell growth |
| US20020082270A1 (en) * | 2000-08-26 | 2002-06-27 | Frank Himmelsbach | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
| ATE340165T1 (de) * | 2001-02-26 | 2006-10-15 | Univ Mcgill | Kombi-moleküle, welche eine inhibierende wirkung auf die signalübertragung und dna-schädigende eigenschaften haben |
| DE10209692A1 (de) * | 2002-03-06 | 2003-09-18 | Merck Patent Gmbh | Isochinolinderivate |
| PE20040945A1 (es) * | 2003-02-05 | 2004-12-14 | Warner Lambert Co | Preparacion de quinazolinas substituidas |
| KR20080095915A (ko) | 2004-05-06 | 2008-10-29 | 워너-램버트 캄파니 엘엘씨 | 4-페닐아미노-퀴나졸린-6-일-아미드 |
-
2005
- 2005-11-22 KR KR1020050111724A patent/KR100735639B1/ko not_active Expired - Fee Related
- 2005-12-20 CN CN2005800455133A patent/CN101094840B/zh not_active Expired - Fee Related
- 2005-12-20 CA CA2592286A patent/CA2592286C/en not_active Expired - Fee Related
- 2005-12-20 RU RU2007128920/04A patent/RU2362773C2/ru not_active IP Right Cessation
- 2005-12-20 NZ NZ556773A patent/NZ556773A/en not_active IP Right Cessation
- 2005-12-20 JP JP2007549242A patent/JP4914372B2/ja not_active Expired - Fee Related
- 2005-12-20 AU AU2005320472A patent/AU2005320472B2/en not_active Ceased
- 2005-12-20 EP EP05819138.8A patent/EP1844022B1/en not_active Expired - Lifetime
- 2005-12-20 MX MX2007007458A patent/MX2007007458A/es active IP Right Grant
- 2005-12-20 US US11/722,096 patent/US8003658B2/en not_active Expired - Fee Related
- 2005-12-20 BR BRPI0519474-1A patent/BRPI0519474A2/pt not_active IP Right Cessation
- 2005-12-20 WO PCT/KR2005/004395 patent/WO2006071017A1/en not_active Ceased
- 2005-12-20 ES ES05819138T patent/ES2427445T3/es not_active Expired - Lifetime
- 2005-12-22 KR KR1020050127660A patent/KR100658891B1/ko not_active Expired - Fee Related
-
2007
- 2007-05-31 IL IL183583A patent/IL183583A/en not_active IP Right Cessation
- 2007-07-27 NO NO20073959A patent/NO20073959L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005320472B2 (en) | 2009-02-26 |
| ES2427445T3 (es) | 2013-10-30 |
| NZ556773A (en) | 2010-10-29 |
| WO2006071017A1 (en) | 2006-07-06 |
| IL183583A0 (en) | 2007-09-20 |
| BRPI0519474A2 (pt) | 2009-01-27 |
| US8003658B2 (en) | 2011-08-23 |
| CA2592286A1 (en) | 2006-07-06 |
| US20080009509A1 (en) | 2008-01-10 |
| RU2362773C2 (ru) | 2009-07-27 |
| KR20060076210A (ko) | 2006-07-04 |
| KR100735639B1 (ko) | 2007-07-04 |
| JP2008525522A (ja) | 2008-07-17 |
| EP1844022A4 (en) | 2009-10-28 |
| IL183583A (en) | 2015-11-30 |
| JP4914372B2 (ja) | 2012-04-11 |
| EP1844022B1 (en) | 2013-08-14 |
| KR100658891B1 (ko) | 2006-12-15 |
| AU2005320472A1 (en) | 2006-07-06 |
| KR20060076186A (ko) | 2006-07-04 |
| RU2007128920A (ru) | 2009-02-10 |
| MX2007007458A (es) | 2007-08-15 |
| CN101094840B (zh) | 2012-10-31 |
| CA2592286C (en) | 2012-05-29 |
| CN101094840A (zh) | 2007-12-26 |
| EP1844022A1 (en) | 2007-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20073959L (no) | Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller | |
| DK2324008T3 (da) | Diarylpyrazol som protein kinase inhibitorer | |
| TW200833693A (en) | Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | |
| EA201070167A1 (ru) | Замещенные производные индазола, активные как ингибиторы киназы | |
| EA200970595A1 (ru) | Производные замещенных индазолов, активные в качестве ингибиторов киназ | |
| WO2009071480A3 (en) | Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors | |
| IS8132A (is) | Pýrósóló-kínasólín afleiður, aðferð við framleiðslu þeirra og notkun sem kínasa hindrar | |
| AU2003244632A1 (en) | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | |
| AU2003227741A1 (en) | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | |
| BRPI0413427A (pt) | derivados de piridilpirrol ativos como inibidores da cinase | |
| AU2003244649A1 (en) | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | |
| WO2008150118A3 (en) | Novel amide derivative for inhibiting the growth of cancer cells | |
| EP2178870A4 (en) | INDOL AND INDAZONE COMPOUNDS AS AN INHIBITORS OF CELL NECROSIS | |
| NO20082088L (no) | Azetidiner som MEK-inhibitorer for behandling av proliferative sykdommer | |
| NO20071617L (no) | Indozolonderivater som 11B-HSD1-inhibitorer | |
| MY174452A (en) | Substituted piperidines that increase p53 activity and the uses thereof | |
| JO2973B1 (en) | Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol | |
| BRPI0413438A (pt) | derivados de pirimidilpirrol ativos como inibidores de cinase | |
| UA102219C2 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы | |
| WO2009032843A3 (en) | Deuterated ethambutols and their use | |
| UA97348C2 (en) | HETEROCYCLIC NF-kB INHIBITORS | |
| EA200870223A1 (ru) | Производные бензоизоиндола для лечения боли | |
| WO2009117467A3 (en) | Therapeutic compounds | |
| EA201000889A1 (ru) | Тризамещенные пиперидины в качестве ингибиторов ренина | |
| WO2007052167A3 (en) | Stable composition for a pharmaceutical formulation containing olanzapine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CREP | Change of representative |
Representative=s name: TANDBERGS PATENTKONTOR AS, POSTBOKS |
|
| RE | Reestablishment of rights (par. 72 patents act) |